



SYNTAXIN APPOINTS EXECUTIVE CHAIRMAN

Abingdon, September 30th, 2009: Syntaxin, a biopharmaceutical company developing novel biologic drugs that control cell secretion, today reports that Andrew Sandham has been appointed Executive Chairman. This follows the resignation of CEO, Patrick Doyle, for personal reasons. Mr Sandham has worked closely with Syntaxin since its formation in 2005, as chairman of the board. A search has been initiated for the vacant position of CEO.

--ends--

Enquiries:

Syntaxin Ltd
Andrew Sandham, Executive Chairman

Tel: +44 (0)1235 552112

About Syntaxin (www.syntaxin.com):

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Syntaxin finalized a Series B financing of £16m in October 2007, which was co-led by SR One, the venture capital arm of GSK, and LSP (Life Science Partners) with additional funds from Syntaxin's existing shareholder, Abingworth. New investors Johnson & Johnson Development Corporation (JJDC) and Quest for Growth also participated in the financing.